Balance Sheet

Cash Flow Statement

Amortization Amortization Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Amortization - Goodwill Cost of Revenue Depreciation & Amortization (IS)EBIAT Gross Profit Leases Other Gross PP&E Adjustments Other Gross PP&E Adjustments Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Legend Biotech (LEGN) Shares Issued (2020 - 2025)

Legend Biotech filings provide 6 years of Shares Issued readings, the most recent being $1.3 million for Q3 2025.

On a quarterly basis, Shares Issued fell 76.48% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.6 million, a 63.1% decrease, with the full-year FY2024 number at $9.7 million, down 17.77% from a year prior.
Shares Issued hit $1.3 million in Q3 2025 for Legend Biotech, up from $273000.0 in the prior quarter.
In the past five years, Shares Issued ranged from a high of $8.1 million in Q2 2023 to a low of $273000.0 in Q2 2025.
Median Shares Issued over the past 5 years was $923000.0 (2022), compared with a mean of $1.7 million.
Biggest five-year swings in Shares Issued: soared 667.48% in 2023 and later plummeted 87.09% in 2025.
Legend Biotech's Shares Issued stood at $378000.0 in 2021, then skyrocketed by 65.08% to $624000.0 in 2022, then fell by 0.48% to $621000.0 in 2023, then fell by 2.9% to $603000.0 in 2024, then soared by 110.95% to $1.3 million in 2025.
The last three reported values for Shares Issued were $1.3 million (Q3 2025), $273000.0 (Q2 2025), and $1.4 million (Q1 2025) per Business Quant data.